BACKGROUND/OBJECTIVES: Risk for developing osteoporosis increases in Asia. The purpose of the study was to evaluate the impact of a high-calcium vitamin D fortified milk (HCM) intervention on parathyroid hormone (PTH) levels, vitamin D status and markers of bone turnover in postmenopausal Chinese women. SUBJECTS/METHODS: Sixty three women (455 years) were assigned to receive two servings of either a calcium/vitamin D fortified milk or a control drink for 12 weeks. PTH, serum 25 (OH)D levels, C-telopeptide of type I collagen (CTX) levels and procollagen type I N-terminal propeptide (PINP) were measured at baseline, 2, 8 and 12 weeks of supplementation. RESULTS: Daily calcium intake at baseline ranged between 260 and 482 mg for the HCM, and 252 and 692 mg for the control group. HCM improved serum 25 (OH)D levels significantly (33.13-39.49 nmol/l), while remaining similar in the control group (29.27-28.21 nmol/l). The difference between the groups were significant at week 2, 8 and 12. The percentage change in PTH levels in the HCM group was significant from week 2 onwards compared to the control drink (Po0.017, Po0.05 and Po0.001 at weeks 2, 8 and 12, respectively). Plasma CTX of the HCM group reduced by 25% between weeks 0 and 2, remaining significantly lower and at similar levels up to week 12. The difference between the HCM and control group for PINP reached significance at weeks 8 (P ¼ 0.011) and 12 (P ¼ 0.003). CONCLUSIONS: The HCM intervention significantly improved vitamin D status and reduced bone turnover over 12 weeks in postmenopausal Chinese women.
INTRODUCTION
The incidence of osteoporosis is increasing in Asia, 1,2 and according to the International Osteoporosis Foundation's 2009 Asian Audit, the incidence of hip fracture has risen from two to threefold in most Asian countries over the past 30 years. 3 In China, more than 69.4 million Chinese, of which 54 million are women over the age of 50, are affected by osteoporosis and there are up to 687 000 hip fractures per year. 3 Low calcium intake and insufficient vitamin D status have been reported as being risk factors for osteoporosis among Asian women. 2 Dairy consumption in Chinese populations is low but milk is potentially of benefit for bone health. 4 The recommended minimum daily requirement for calcium in Chinese women is set at 1000 mg/day 5 but several studies report intakes as low as 230-724 mg/day 1, 6, 7 and higher dietary calcium intake was associated with higher bone mass. 7 A study in Chinese women living in Hong Kong showed that bone loss can be reduced by supplementing with 800 mg calcium per day using fortified milk. 8, 9 Similarly, a study in Chinese women in Malaysia showed that supplementing with 1200 mg calcium per day from fortified milk significantly reduced the percentage of total body bone loss compared to the control group. 6 Milk supplementation was also of benefit in young Chinese women and girls, increasing the bone mass over 6 months and 2 years, with some effect on markers of bone resorption. 4, 10 These fortified milks also contained vitamin D ranging from 5 to 10 mg/day, which resulted in improved vitamin D status in all four studies.
In short-term studies, the measurement of biochemical markers to assess bone turnover offers an accepted means of determining the effect of a treatment or dietary supplement on bone metabolism before any significant change in actual bone density. 11 The markers reflect whole body rates of bone resorption and formation, and are helpful in assessing the dynamics of metabolic imbalance. Several studies have now shown that increased levels of bone resorption markers are associated with an increased risk of fracture, 12 suggesting that increased bone resorption leads to microarchitectural deterioration of bone tissue due to perforation of the trabeculae. 12, 13 These markers are sensitive and respond quickly to interventions. In South East Asian postmenopausal women, fortified milk rapidly reduced bone resorption and bone turnover markers within weeks of starting supplementation. 14 We aimed to evaluate the impact of a high-calcium vitamin D fortified milk (HCM) intervention in women potentially at risk of developing osteoporosis due to low calcium intakes and vitamin D deficiency, but in whom marker levels are closer to the reference 1 ranges for postmenopausal women. We hypothesised that bone resorption will reduce significantly within the 12 weeks of supplementation, as measured by serum C-telopeptide (CTX) coinciding with a reduction in plasma parathyroid hormone (PTH) levels and that there would be an improvement in vitamin D status.
MATERIALS AND METHODS
The study was approved by the Ethics Committee of Beijing Friendship Hospital (approval number: (2010)-040; trial registration number: ACTRN12612000329864). The study was run from February to May corresponding to winter/spring in China.
Study population, inclusion and exclusion criteria
Women aged over 55 years of age, at least 5 years postmenopause, with a body mass index (BMI) between 17 and 30 kg/m 2 were recruited. Exclusion criteria included a history of metabolic bone disease, bone mineral density (BMD) measurement below -2.5 s.d. of young normal subjects at the hip or spine, liver or kidney function test outside the normal range; diagnosed diabetes mellitus or insulin resistance, lactose intolerance/milk allergy; regular use of calcium fortified foods or calcium, vitamin D and multivitamin supplements; regular use of anti-acids containing calcium; baseline intake of more than 500 mg calcium per day (based on a 24-h recall); more than two units of alcohol per day; smoking; regular use of medication that may influence bone mass; rheumatoid arthritis/autoimmune disease and fractures in the last 6 months.
Randomisation criteria, procedures and intervention
Recruitment. A total of 546 women, already on the database of the Clinical Centre and Basic Research (CCBR) Beijing, were assessed for eligibility based on previous bone density measurements; out of these, 130 women were further screened for general health including BMD measurements using a GE Lunar Prodigy (GE Healthcare Technologies, Madison, WI, USA) bone densitometer (CV% ¼ 0.4). Twenty-five women were excluded on the basis of having high blood glucose, insulin resistance, hyperlipidemia or abnormal liver or kidney function, and five were excluded on the basis of having osteoporosis. No women were excluded based on their daily calcium intake. Sixty three women were randomised using central randomisation by computer (Figure 1 ).
Intervention. The women were randomised into two groups of B30 volunteers each. One group (n ¼ 31) was assigned to receive two servings per day of a powdered control rice-based drink and the second group (n ¼ 32) to receive two servings per day of HCM (Anlene, Fonterra Brands, Singapore PTE Ltd, Singapore) for 12 weeks ( Table 1 ). The HCM drink provided 900 mg calcium, 96 mg magnesium, 2.4 mg zinc and 6.4 mg vitamin D per day. The milk powders were provided in a sachet containing a scoop to measure the correct amount of powder to be reconstituted in 200 ml potable water for each serve.
Screening visit
A screening questionnaire on general health was administered at an initial visit. A blood sample was taken between 0800 and 1000 hours, after an overnight fast, and haematology, blood minerals and metabolic markers were assessed. If the blood tests results were normal, study subjects were asked to have a BMD (DXA) measurement of hip and spine (L1-L4). Body weight was measured to the nearest 0.2 kg using a beam balance, and standing height was measured to the nearest 0.1 cm using a stadiometer. Medical history of each subject was recorded at this visit.
Intervention Baseline Blood sampling. Replicate blood samples, 3 days apart, were taken between 0800 and 1000 hours (after an overnight fast) for the baseline measurements. Samples were taken on both days for plasma markers of bone turnover: CTX and procollagen type I N-terminal propeptide (PINP). Serum calcium, magnesium, phosphorus, lipid profile, glucose, insulin, PTH and 25 (OH)D were only measured in the first day's samples. The samples for the minerals and metabolic health were collected, processed and analysed by local diagnostic laboratories. Plasma samples for the bone markers, 25 (OH)D and PTH were snap frozen and stored at -70 to À 80 1C until the end of the trial and then analysed together.
Anthropometry. Methodology as per screening visit.
Questionnaires completed at baseline. A 3-day diet record, 24-h calcium recall, physical activity, demographics and a list of all medication taken in the last 6 months were recorded at baseline.
Follow-up measurements (week 2 and 8).
On weeks 2 and 8, replicate blood samples, 3 days apart, were taken between 0800 and 1000 hours (after an overnight fast) for mineral and bone marker measurements. Collection and analysis of the samples was conducted as per the baseline visit. 
Compliance
Milk powder was dispensed to each subject at baseline, week 8 and 12.
Unused milk powder was returned by the subjects to the investigator site for a consumption check. At week 4 a phone call was made to monitor milk consumption of the subjects. Each subject was asked to record the milk powder intake on each day in a diary provided at baseline. At each visit these consumption record diaries were cross-checked with subjects.
Statistical analyses
Based on the published data, the within subject standard deviation for the primary outcome variable, CTX, was estimated to be 0.045 ng/ml and a representative mean CTX value is taken to be 0.23 ng/ml. The corresponding standard deviations of the treatment difference and the treatment difference for replicate measurements were calculated as 0.064 and 0.045 ng/ml, respectively. To detect a difference of 20% (that is, 0.046 ng/ml) with a power of 90% and an alpha of 5%, we required 22 subjects per group, if two replicate measurements will be taken at each time point. To allow for a dropout rate of 25%, the number of volunteers required was increased to 30 per group. Values from replicate blood samples taken 3 days apart in the same week were averaged for analysis. SAS (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. Mixed models approach to repeated measures was used and the reported P-values for the effects of treatment group, time and their interaction were based on a suitable covariance pattern model. The baseline results (week 0) and change in BMI between 0 and 12 weeks were included in the model as covariates and the repeated-measures analysis was based on the results obtained during the intervention (that is, weeks 2, 8 and 12). ANOVA was followed by post-hoc comparisons of treatment means using the Tukey-Kramer test. Measurements were considered to be significantly different if Po0.05. Table 2 depicts the baseline characteristics of the two groups of women who participated in the trial. There were no significant differences in the baseline characteristics between the two groups. The BMDs of the women were within the normal range, although on average had negative T scores for both lumbar spine and femoral neck. Reported calcium intake was low (o500 mg/day). All women had insufficient serum 25 (OH)D levels (o50 nmol/l). The body mass (65.88-65.03 kg (P ¼ 0.001)) as well as BMI (26.1-25.7 kg/m 2 (P ¼ 0.007)) of the HCM group declined significantly over the 12-week period.
RESULTS

Demographics and baseline characteristics
Compliance/adherence There were two adverse events, one woman withdrew due to constipation and stomach discomfort, one woman withdrew due to unrelated cancer, and three women withdrew their informed consent voluntarily. All withdrawals were from the HCM group. In all, 31 women completed in the control group and 27 completed in the HCM group. Compliance for the subjects who completed the trial was 98%.
General health and blood minerals For both groups of women, general measures of health including blood glucose, insulin and lipid profile were within normal ranges at week 0 and 12 (data not shown). There were no significant differences between the HCM and control groups except for serum insulin, which was significantly higher in the HCM group versus the control group (Po0.05). Blood minerals including calcium, magnesium and phosphorus were within the normal ranges for both cohorts, and there were no significant differences between the HCM and the control group (data not shown).
Nutrient intake
The women had a low calcium intake as measured using a 2-3 day food recall. Intakes were 376 mg (median; 260-482, interquartile range) for the control group and 427 mg (median; 252-692, interquartile range) for the HCM group. Magnesium and phosphorus intakes were within the recommended daily intakes. Other nutrients including energy, protein, fat and carbohydrate were not significantly different between groups.
Vitamin D status At baseline, mean serum 25 (OH)D levels were insufficient (o50 nmol/l) in both the control (29.27 (12.03) nmol/l) and HCM groups (33.13 (15.51) nmol/l) ( Table 2 ). During supplementation with the control milk, the serum 25 (OH)D 3 levels remained very similar (29.27-28.21 nmol/l) but increased significantly over the 12 weeks of supplementation in the HCM group (33.13-39.49 nmol/l; Po0.001) (Figure 2a ). There was no significant difference in vitamin D status between groups at week 0, but a significant difference in weeks 2, 8 and 12. Figure 2b shows the change in vitamin D status in the two groups of subjects from baseline to week 12 of supplementation. Among the control group, 38% (12/31) were deficient, 54% (17/31) insufficient and 6% (2/31) sufficient at baseline. Over the 12 weeks of supplementation, the percentage with deficiency increased to 45% (14/31), with 51% (16/31) being insufficient and 3% (1/31) sufficient. In the HCM group, 37% (12/32) were deficient, 53% (17/ 32) insufficient and 9% (3/32) sufficient at baseline. Their status changed to 3% (1/27) being deficient, 77% (21/27) insufficient and 18% (5/27) sufficient over the 12 weeks of supplementation.
Parathyroid hormone levels Figure 3 and Table 3 depict the changes in PTH over the 12 weeks of supplementation. There was a significant time-by-treatment interaction effect on PTH levels (Po0.001). The percentage change in PTH levels in the HCM group was significant at week 2, 8 and 12 compared with the control drink (Po0.017 at week 2, P ¼ 0.02 at week 8 and o0.001 at week 12).
Changes in bone turnover markers Figure 4 and Table 3 show the changes in CTX, over the 12 weeks of supplementation. Mean plasma CTX values were approximately 0.4 mg/l at baseline. With HCM supplementation, plasma CTX reduced by 25% between weeks 0 and 2, remaining at similar levels up to week 12 (26%). The CTX levels in HCM group were significantly lower than in the control group with Po0.001 at week 2, 8 and 12.
PINP responded slightly later than CTX, and comparisons between HCM and control groups reached significance at weeks 8 (P ¼ 0.011) and 12 (P ¼ 0.003) ( Figure 5 ; Table 3 ).
DISCUSSION
Supplementation of healthy postmenopausal Chinese women with calcium and vitamin D fortified milk for 12 weeks significantly reduced plasma PTH levels, reduced bone turnover and improved vitamin D status. In addition, supplementation resulted in significantly reduced body weights and lower mean BMIs in the HCM group. A similar reduction in body weight and BMI was observed when supplementing with HCM in women from the Philippines. 15 Habitual mean calcium intake of less than 500 mg/day was below the recommended intake of 1000 mg for Chinese women. 4, 16 An intake of sufficient calcium is essential to maintain metabolic functions together with bone turnover. Low calcium intake combined with a decrease in calcium absorption with ageing could contribute to an increase in fracture risk for older Chinese women. 5 Calcium absorption also varies with vitamin D status 17 and may be compromised in this population. The women generally had low levels of serum 25 (OH)D and most were significantly insufficient in vitamin D. The minimum level of serum 25 (OH)D estimated to be optimal for fracture prevention varies between 50 and 80 nmol/l according to Dawson-Hughes et al. 18 and National Institutes of Health (http:// ods.od.nih.gov/factsheets/vitamind). Levels of 30-50 nmol/l are generally considered insufficient for bone and overall health, while levels below 25 nmol/l are considered deficient. At the start of the trial, up to 38% of the women were deficient in 25 (OH)D, up to 54% were insufficient and only 6-9% were sufficient. Very high rates of vitamin D insufficiency have also been reported for adults living in China and specifically for women in Beijing. 16 Wat et al.
19
reported 62% insufficiency in 382 community dwelling Chinese adults observed in Hong Kong, while Yan et al. 20 reported that 15% of 48 older women living in Shenyang were deficient in 25(OH)D. The present intervention trial was run during winter and spring in China. Beijing lies at latitude 391 north with an average January temperature of À 4.2 1C, which will limit the time women spend outdoors and their sun exposure. 16 Pollution and cloud cover may also have contributed to the poor vitamin D status. Even though the change in vitamin D status was small, it did indicate that supplementation with vitamin D would be of benefit over a longer period of time, and therefore contributing to improvement of bone health. 6, [8] [9] [10] 14 Vitamin D insufficiency increases PTH levels, and chronically elevated PTH levels will increase bone turnover and especially cortical bone loss. 16 Furthermore, several studies in postmenopausal women have reported not only an inverse relationship between 25 (OH)D and PTH but also with BMD. [21] [22] [23] [24] [25] A population study confirmed that raising vitamin D status step wise to sufficiency is accompanied by a significant increase in BMD at all sites. 26 In addition, there is a strong association between vitamin D deficiency and hip fractures, 27 which together with low calcium intakes indicate that older women in China may be at significant risk of fracture.
Milk supplementation (900 mg calcium; 6.4 mg vitamin D) significantly reduced the levels of PTH after only 2 weeks. The mean vitamin D status of the intervention group was significantly improved between weeks 0 and 8 (from 33 to B40 nmol/l) and was also significantly higher than the control group at week 8. Dawson-Hughes et al. 28 estimated that an intake of 2.5 mg of 25(OH)D will raise serum levels by 2.75 nmol/l at low starting levels, but that the dose required to raise 25 (OH)D sufficiently will vary due to BMI, starting vitamin D status, associated PTH levels and sun exposure. In the present study, daily vitamin D intake was raised by 6.4 mg/day for 12 weeks and although this resulted in HCM supplementation resulted in a significant reduction in bone turnover as well as bone resorption. The mean CTX at baseline was between 0.42 and 0.45 mg/ml, which is within the range previously reported for postmenopausal women. 12, 30 After the intervention with HCM, the mean CTX levels decreased by 25% within 2 weeks of supplementation, falling to levels similar to those reported for premenopausal women residing in France, Belgium, USA and the UK (0.29-0.31 mg/l).
12,31,32
The baseline levels of PINP measured in our group (40-47 mg/l) are higher than those reported by Liu et al. 33 for 244 postmenopausal Chinese women aged between 45 and 65 years. PINP is the degraded product of type I collagen in the extracellular matrix and circulating PINP mainly reflects the synthesis rate of type I collagen and the bone turnover rate. 34 Bone turnover increases with ageing and menopausal stage, which could partly be reflected in the values reported in this study, but there is also the additional impact of low vitamin D status and low habitual calcium intakes in our group of women increasing overall bone turnover. 21, 34 In this study, PINP responded to fortified milk supplementation, decreasing by 7% at week 8 and by 12% at week 12.
Supplementing with calcium and vitamin D reduced bone turnover in our studies, with the response lagging for up to 6 weeks behind that of CTX. It is likely that as bone resorption decreases and then stabilizes with supplementation, bone formation will also initially decrease and then plateau to reach a steady state. This is due to the coupling of osteoclast and osteoblast activities, so that once resorption has slowed, so too will formation, as there are fewer resorption cavities to be filled. 35, 36 There have been few studies with calcium, vitamin D or milk supplementation in older Chinese women, including bone turnover markers. Supplementation with 20 mg/day 25(OH)D for 3 months improved vitamin D status and significantly reduced CTX levels in postmenopausal women residing in Shanghai. 29 Huang et al. 37 reported a reduction in PTH levels, bone resorption and bone loss in postmenopausal Chinese women in response to 1000 mg calcium and 10 mg of vitamin D for 12 months. Fortified milk supplementation (800 mg calcium; 6 mg vitamin D) for 3 years improved vitamin D status and prevented bone loss in postmenopausal Chinese women residing in Hong Kong. 8, 9 In our study, HCM significantly impacted on markers of bone resorption and formation. These markers can be predictive of future bone loss 38 and future risk of fracture 36 independent of BMD, 39 as high turnover can affect trabecular architecture and increase the incidence of perforation, thereby reducing bone strength. A study supplementing 9605 community-dwelling elderly adults (466 years of age) with 1000 mg calcium and Values are given as least-squares mean (s.e.). n ¼ 31 for control group and n ¼ 27 for HCM group. At baseline, control group n ¼ 31; HCM group n ¼ 32. At week 2, control group n ¼ 31; HCM group n ¼ 28. At week 8, control group n ¼ 31; HCM group n ¼ 27. At week 12, control group n ¼ 31; HCM n ¼ 27. 20 mg vitamin D reported a 16% fracture reduction, 40 and recent meta-analyses confirm the need for additional calcium with vitamin D supplementation to prevent bone loss and possibly fractures in people aged 50 years and older. 20, 41, 42 In conclusion, the addition of calcium and vitamin D fortified milk to the diet of postmenopausal Chinese women significantly reduced bone resorption, lowered PTH levels and improved vitamin D status within 2-8 weeks. We therefore accept our hypothesis. If sustained long term, these could help preserve BMD and reduce fracture risk. Owing to the large and rapidly ageing populations in Asia, and the high incidence of vitamin D insufficiency, 16, 19, 20 supplementation of their traditionally low calcium diets with a fortified milk drink may have a significant public health impact.
